Home › Diffuse Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma clinical trials recruiting in the U.S.
105 studies for Diffuse Large B-Cell Lymphoma are recruiting participants at sites across the United States.
Cities with the most studies
- New York City, NY20 studies
- Baldwin Park, CA19 studies
- Los Angeles, CA18 studies
- Houston, TX18 studies
- Chicago, IL18 studies
- Milwaukee, WI17 studies
- Nashville, TN17 studies
- Boston, MA17 studies
- Philadelphia, PA15 studies
- Durham, NC15 studies
- Portland, OR15 studies
- Cleveland, OH13 studies
- Seattle, WA13 studies
- Dallas, TX13 studies
- Washington, DC13 studies
- Salt Lake City, UT12 studies
- Richmond, VA11 studies
- Denver, CO11 studies
- Cincinnati, OH11 studies
- Rochester, MN10 studies
- Columbus, OH10 studies
- Atlanta, GA10 studies
- Jacksonville, FL9 studies
- Omaha, NE9 studies
- Louisville, KY9 studies
- Cedar Rapids, IA9 studies
- Grand Rapids, MI8 studies
- Edison, NJ8 studies
- St. Louis, MO8 studies
- San Antonio, TX8 studies
- San Francisco, CA8 studies
- New Haven, CT8 studies
- Miami, FL8 studies
- Indianapolis, IN7 studies
- Charlottesville, VA7 studies
- Aurora, CO7 studies
- Kansas City, MO7 studies
- Sacramento, CA6 studies
- Baltimore, MD6 studies
- Detroit, MI6 studies
By state
- Alabama4 studies
- Arizona13 studies
- Arkansas4 studies
- California43 studies
- Colorado19 studies
- Connecticut8 studies
- District of Columbia4 studies
- Florida25 studies
- Georgia15 studies
- Idaho4 studies
- Illinois22 studies
- Indiana9 studies
- Iowa11 studies
- Kansas6 studies
- Kentucky12 studies
- Louisiana7 studies
- Maryland15 studies
- Massachusetts17 studies
- Michigan17 studies
- Minnesota15 studies
- Missouri8 studies
- Montana3 studies
- Nebraska9 studies
- Nevada3 studies
- New Jersey14 studies
- New Mexico3 studies
- New York29 studies
- North Carolina20 studies
- North Dakota4 studies
- Ohio25 studies
- Oklahoma5 studies
- Oregon15 studies
- Pennsylvania19 studies
- South Carolina4 studies
- South Dakota3 studies
- Tennessee20 studies
- Texas31 studies
- Utah14 studies
- Virginia17 studies
- Washington18 studies
- Wisconsin20 studies
Recently updated studies
A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 13, 2026 · NCT07519772A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 13, 2026 · NCT06717347A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 13, 2026 · NCT06890884Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
RecruitingPhase 1/2
Ages 18 to 120 · All sexes · Updated Nov 12, 2026 · NCT03223610Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT05272384Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT06806033A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT07735533Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 9, 2026 · NCT04002947Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 9, 2026 · NCT06649812Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT05852717AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study")
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT07649304A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT06091865A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT07101328A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT07188558Auto Stem Cell Transplant for Lymphoma Patients
RecruitingPhase 2
Up to age 75 · All sexes · Updated Nov 4, 2026 · NCT03125642A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT07226843A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT05139017Pivotal Study to Validate a Novel System to Non-Invasively Detect Severe Neutropenia
RecruitingObservational study
Ages 10 and older · All sexes · Updated Nov 3, 2026 · NCT06323447A Study of ARC-02 in B-cell NHL
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 2, 2026 · NCT07691606A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma
RecruitingPhase 2
Ages 65 to 80 · All sexes · Updated Oct 30, 2026 · NCT06765317Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL
RecruitingPhase 2
Ages 65 to 99 · All sexes · Updated Oct 30, 2026 · NCT05952024Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
RecruitingPhase 1/2
6 Months – 25 Years · All sexes · Updated Oct 30, 2026 · NCT06395103Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 30, 2026 · NCT06500273Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
RecruitingObservational study
Ages 0 to 38 · All sexes · Updated Oct 29, 2026 · NCT06131801Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 28, 2026 · NCT05890352From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.